S&P 500   3,002.85 (+0.56%)
DOW   26,800.61 (+0.11%)
QQQ   193.15 (+0.76%)
AAPL   240.62 (+1.78%)
FB   189.23 (+1.82%)
MSFT   137.84 (+0.31%)
GOOGL   1,246.24 (+0.15%)
AMZN   1,775.01 (+1.00%)
CGC   20.08 (-0.64%)
NVDA   196.06 (+2.92%)
MU   44.99 (+3.50%)
GE   8.86 (-1.12%)
TSLA   255.19 (-0.68%)
AMD   32.16 (+3.84%)
T   38.36 (-0.29%)
F   9.11 (-1.94%)
ACB   3.61 (-1.90%)
NFLX   275.33 (+0.01%)
BAC   31.03 (+2.21%)
GILD   64.99 (+0.12%)
S&P 500   3,002.85 (+0.56%)
DOW   26,800.61 (+0.11%)
QQQ   193.15 (+0.76%)
AAPL   240.62 (+1.78%)
FB   189.23 (+1.82%)
MSFT   137.84 (+0.31%)
GOOGL   1,246.24 (+0.15%)
AMZN   1,775.01 (+1.00%)
CGC   20.08 (-0.64%)
NVDA   196.06 (+2.92%)
MU   44.99 (+3.50%)
GE   8.86 (-1.12%)
TSLA   255.19 (-0.68%)
AMD   32.16 (+3.84%)
T   38.36 (-0.29%)
F   9.11 (-1.94%)
ACB   3.61 (-1.90%)
NFLX   275.33 (+0.01%)
BAC   31.03 (+2.21%)
GILD   64.99 (+0.12%)
Log in

Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$18.53
+0.38 (+2.09 %)
(As of 10/21/2019 11:30 AM ET)
Today's Range
$18.15
Now: $18.53
$18.64
50-Day Range
$17.14
MA: $19.94
$22.97
52-Week Range
$17.11
Now: $18.53
$42.69
Volume14,528 shs
Average Volume1.20 million shs
Market Capitalization$2.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.09 billion
Cash Flow$0.65 per share
Book Value$7.54 per share

Profitability

Net Income$-139,310,000.00

Miscellaneous

Employees2,300
Market Cap$2.91 billion
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.


Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings data on Thursday, July, 25th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.20. The firm earned $279.90 million during the quarter, compared to the consensus estimate of $251.40 million. Alkermes had a negative net margin of 17.10% and a negative return on equity of 4.13%. The business's revenue for the quarter was down 8.1% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. View Alkermes' Earnings History.

When is Alkermes' next earnings date?

Alkermes is scheduled to release their next quarterly earnings announcement on Wednesday, October 23rd 2019. View Earnings Estimates for Alkermes.

How can I listen to Alkermes' earnings call?

Alkermes will be holding an earnings conference call on Wednesday, October 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2019 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.14-1.19 billion, compared to the consensus revenue estimate of $1.17 billion.

What price target have analysts set for ALKS?

11 brokerages have issued 1-year price objectives for Alkermes' stock. Their forecasts range from $20.00 to $36.00. On average, they anticipate Alkermes' share price to reach $28.70 in the next year. This suggests a possible upside of 54.9% from the stock's current price. View Analyst Price Targets for Alkermes.

What is the consensus analysts' recommendation for Alkermes?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss and sales beat estimates in the first quarter of 2019. With the increasing traction of Aristada in the market, the company continues to emerge as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline, highlighted by the planned submission of the NDA for ALKS 3831 and the regulatory review of the recently submitted NDA for diroximel fumarate for multiple sclerosis, with action expected in the fourth quarter. The company also expects to release data from ALKS 4230's anti-tumor response study in 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date. Alkermes has a positive record of earnings surprises in recent quarters." (7/19/2019)
  • 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating for ALKS stock and are reducing our PT by $5 to $41. We believe the FDA advisory panel view of the ALKS-5461 NDA is a major setback not only for the drug but also to the ability of ALKS to convince investors that the company can develop proprietary therapies of meaningful commercial potential." (11/5/2018)

Has Alkermes been receiving favorable news coverage?

News headlines about ALKS stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alkermes earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Alkermes.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Celgene (CELG), AbbVie (ABBV), Netflix (NFLX), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Starbucks (SBUX), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.14%), Fox Run Management L.L.C. (0.01%), Nisa Investment Advisors LLC (0.01%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Laurie Keating, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Which institutional investors are buying Alkermes stock?

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Fox Run Management L.L.C., Nisa Investment Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $18.53.

How big of a company is Alkermes?

Alkermes has a market capitalization of $2.91 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

What is Alkermes' official website?

The official website for Alkermes is http://www.alkermes.com/.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (NASDAQ ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  550 (Vote Outperform)
Underperform Votes:  419 (Vote Underperform)
Total Votes:  969
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: What is the NASDAQ?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel